My Pitch: "52-Week Range 0.0270 - 0.3982
Symbol change: BTHCF
the areas of non–alcoholic steatohepatitis (NASH), chronic kidney disease (CKD), inflammatory bowel disease (IBD) and idiopathic pulmonary fibrosis (IPF)
"

My Pitch: "Flying Under The Radar

Data Readout - Due Q4 2020: COVID-19

Data Readout - Due Q1 2021: Chronic Cough

Data Readout - Due Q4 2021: Idiopathic Pulmonary Fibrosis"

My Pitch: "cool"

My Pitch: "$AGNPF Algernon Receives Regulatory and Ethics Approval for Phase 2 Ifenprodil COVID-19 Human Study in South Korea

The 40-patient, 4-week trial, is designed to test the effect of Ifenprodil in COVID-19 infected patients with severe pneumonia.


Enrollment is expected to begin 5/8/20"

My Pitch: "The company's technology addresses a multi-trillion dollar healthcare diagnosis industry. It's a no brainer and they have a two prong technology approach (NaNose and FAIMS). "

My Pitch: "disruptive tech. stock is insanely cheap right now."

My Pitch: "Blozf sister company"

My Pitch: "All of the blogs on BLOZF about BTHCF and the listing of the upper management including Dr. Yost and the many chemical and medical applications convinced me to buy last week. I was in Chemistry then Medicine and have communicated with Dr. Yost and was very impressed by him."

My Pitch: "DNA in saliva, saliva in breath....the future of medical testing...among other tests"

My Pitch: "Ahhheeeee"

My Pitch: "Green Rush"

My Pitch: "Best pennies I ever spent! BTHCF and BLOZF with Yost group and Haick have 3rd party validation like no other OTC company in the game. "